Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Andalusia
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Artificial intelligence (AI)
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bioresorbable stents
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Case study
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
See all tags

Weekly summary of MTRC Instagram account

On the week of 6th of January, MTRC published several analytical posts:

  • Process of DRG change in England
  • List of technologies with different levels of added value (ASA) in France
  • Countries offering access to hospital procedure volume information
  • Improvements with glaucoma minimally invasive surgery reimbursement in England
  • Role of DRG in Scandinavia
  • List of countries actively using the DRG system for case-by-case reimbursement.

Follow us on Instagram on mtrc.market.access

Tags
Services of MTRC

The latest related news

08
Apr 2024

MTRC launched Knowledge Zone with brief overviews of the market access landscape and challenges for individual types of medical technologies in Europe

Market access is a rapidly changing field and the landscape varies for different types of medical technologies. To provide an additional, easy-to-access source of high-level information about key themes in the market access landscape and challenges for individual types of medical technologies, MTRC launched a dedicated Knowledge Zone on the website. Currently, the Knowledge Zone includes information about procedure coding, payment mechanisms, policy considerations, HTA, and future challenges for market access for 12 types of medical technologies. In the coming weeks, the Zone will expand 40 key technology groups
Read more
26
Feb 2024

Watch new short videos on the MTRC YouTube channel

MTRC released several short (2-4 minutes) educational videos on its YouTube channel: “Three common market access barriers for medical technologies”, “Reimbursement models and incentives for healthcare providers”, “How to spot a well-functioning DRG system?” and “Market access challenges for different types of medical technologies”. Videos can be of interest to an audience of both market access professionals and those new to the field of reimbursement, funding, HTA and market access for medical technologies in Europe.
Read more
12
Feb 2024

MTRC released a White Paper with a summary of clinical evidence requirements for the LPPR process for implants and invasive devices in France

In a new White Paper, MTRC identified evidence requirements for national add-on reimbursement via the LPPR List process based on analysis of five recent HAS reports with positive recommendations. Cases included technologies with different levels of added clinical value (II, III, IV, and V). A review of five cases is followed by recommendations in relation to evidence generation for medical technologies in France, and factors influencing the decision-making of HAS. The analysis was performed in February 2024.
Read more